A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination
2022-06-29
عنوان الدراسة
A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination
داعم الدراسة
Roche
دواء الدراسة
Bevacizumab
رقم بروتوكول الدراسة
ML18147
حالة الدراسة
Completed
موقع الدراسة
KFSH
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。